Scottish soldier-heroes and patriotic war heroines: the gendered politics of World War I commemoration

This paper explores the (re)production of embodied gendered and racialised identities as part of commemorations devised by the Scottish government to mark the Centenary of WWI, 2014- 18. In particular, we demonstrate how the Centenary has re-established Scotland’s key contribution to British military power instead of providing a platform for a broader discussion of British wars and Scotland’s role therein. Our analysis posits that this reframing was achieved through the (re)production of a gendered polarisation between white ‘dead’ soldier-heroes, ‘local lads’ and bearers of a ‘proud Scottish military tradition’; and women as embodiments of patriotic motherhood. We further explore the deployment of specific discursive and performative means to transform Dr Elsie Inglis, the only woman whose contribution was singled out by WW100 Scotland, into a patriotic war heroine. This was achieved by the militarisation of her work; the obscuring of identity, class- and race-based hierarchies within women’s war-work; and, finally, through the subversion of feminist ideas and practices in Inglis’ work for the Scottish Women’s Hospitals. Lastly, we reflect on the gendered legacy of the Centenary, emphasising the necessity for critical engagement with Britain’s wars and Scotland’s role therein

The politics and pedagogy of war remembrance

Drawing on analysis of learning materials, interviews and ethnographic observations of Scottish education, we analyse how projects aimed at teaching children to remember wars instil war normalising logics through (a) substitution of self-reflective study of conflict with skill-based knowledge; (b) gendered and racial stereotyping via emphasis on soldier-centric (Scottish/British) nationalisms, localisation and depoliticisation of remembrance; (c) affective meaning-making and embodied performance of ‘Our War’. Utilising Ranciere-inspired critical pedagogy, we explore opportunities for critical engagement with the legacy of conflicts

Acetazolamide: old drug, new evidence?

Acetazolamide is an old drug used as an antiepileptic agent, amongst other indications. The drug is seldom used, primarily due to perceived poor efficacy and adverse events. Acetazolamide acts as a noncompetitive inhibitor of carbonic anhydrase, of which there are several subtypes in humans. Acetazolamide causes an acidification of the intracellular and extracellular environments activating acid-sensing ion channels, and these may account for the anti-seizure effects of acetazolamide. Other potential mechanisms are modulation of neuroinflammation and attenuation of high-frequency oscillations. The overall effect increases the seizure threshold in critical structures such as the hippocampus. The evidence for its clinical efficacy was from 12 observational studies of 941 patients. The 50% responder rate was 49%, 20% of patients were rendered seizure-free, and 30% were noted to have had at least one adverse event. We conclude that the evidence from several observational studies may overestimate efficacy because they lack a comparator; hence, this drug would need further randomized placebo-controlled trials to assess effectiveness and harm.</p

Is repeat fine needle aspiration required in thyroid nodules with initial benign cytology? Results from a large Irish series

Background : Fine needle aspiration (FNA) cytology is the preferred method for assessing thyroid nodules for malignancy. Concern remains about the rate of false negative results. The primary aim of this study is to investigate the malignancy rate of thyroid nodules initially classified as benign (Thy 2). Methods: We retrospectively examined 658 nodules in 653 (429 female) patients between January 2013 to December 2017. All FNA biopsies (FNABs) were performed under ultrasound (US) guidance by a radiologist with expertise in thyroid pathology. Nodules were cytologically classified according to the UK Royal College of Pathologists guidelines. Decisions about further management were made at a regular thyroid multidisciplinary meeting. Follow up of the Thy 2 nodules was determined based on clinical and radiological criteria. Results: The mean age (± SD) was 53.2 (14.6) years. Five hundred out of 658 (76.0%) nodules were classified as Thy 2 (benign) after the first FNAB. Of these thyroid nodules initially classified as benign, 208 (41.6%) underwent repeat FNAB and 9 (1.8%) were surgically removed without repeat FNAB. The remainder were followed up clinically and/or radiologically. Seven (1.4%) of nodules initially classified as Thy 2 were later shown to be or to harbor malignancy after a follow-up of 74.5 (± 19.7) months. Papillary thyroid microcarcinomas were found co-incidentally in two thyroid glands of benign nodules, giving a true prevalence of 5/500 (1.0%). Conclusions: With a well targeted FNAB, the false negative rate of an initial benign thyroid FNA is very low thus routine second FNAB is not required in patients with a thyroid nodule initially deemed benign. Multidisciplinary input is imperative in informing decision making.</p